CurifyLabs bags €12M to automate personalised medicine

2026-07-06 · Source: Tech.eu - Tech.eu · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Medical Devices & Health Technology, Automation & Robotics · Depth: Fundamental Awareness, quick

Summary

Finnish health technology company CurifyLabs, founded in 2021, has secured €12 million in Series A funding to advance its automated personalized medicine manufacturing platform. The round was co-led by Sandwater and HealthCap, with participation from Tesi, existing investor Lifeline Ventures, and US customers and employees. This investment will facilitate expansion of US operations, strengthen the supply chain, and accelerate product development, including the PharmaPrinter Aurum. CurifyLabs' Compounding System Solution combines proprietary software, GMP-manufactured excipient bases, and three-dimensional printing technology. This automates pharmaceutical compounding, enhancing consistency, precision, and speed over manual processes. Its technology is currently utilized by pharmacies in twenty-one US states and across Europe.

Key takeaway

For investors evaluating health tech, CurifyLabs' €12 million Series A funding signals strong market validation for automated personalized medicine. This investment supports critical US expansion and supply chain strengthening, indicating a robust growth trajectory. Consider their 3D printing and software platform, already deployed in 21 US states. It addresses demand for consistent, precise, and efficient pharmaceutical compounding. Your due diligence should assess their ability to scale this technology globally.

Key insights

Automated pharmaceutical compounding via 3D printing and software improves personalized medicine manufacturing.

Principles

• Automate pharmaceutical compounding for consistency.
• Integrate quality control into manufacturing.
• Enhance precision and speed over manual processes.

Method

The Compounding System Solution uses proprietary software, GMP-manufactured excipient bases, and three-dimensional printing to automate medicine preparation.

In practice

• Pharmacies use the technology in 21 US states.
• PharmaPrinter Aurum is a new platform product.

Topics

• Personalized Medicine
• Automated Compounding
• 3D Printing
• Health Technology
• Series A Funding
• PharmaPrinter Aurum

Best for: Investor, Entrepreneur, Tech Journalist

Related on AIssential

• Graph Therapeutics brings total funding to over $10M to advance precision immunology — AI-powered analysis of live patient cells, multi-omics data, and functional biology decodes immune dysfunction for precision immunology.
• Tissium raises €30M in equity funding, €30M in debt — Tissium's biomorphic programmable polymers offer a non-invasive tissue repair solution, securing significant funding for US expansion.
• WellSync Reports Strong BoomRx Momentum with More Than $70-Million Annualized Run Rate — Integrated pharmaceutical technology platforms are crucial for scaling virtual care and addressing supply chain complexities.
• Exclusive: Fathom raises $47M, blending AI and physics in drug discovery - Endpoints News — Fathom Therapeutics combines AI and physics-based simulations to accelerate drug discovery.
• Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468] — Proactive health strategies, leveraging existing and AI-accelerated medicines, can drive a trillion-dollar public health revolution.
• French Tech Funding Wire February 16: Tech500 Hiring Jumps 33%; DentalMonitoring €84M Round Leads 13 Deals For €235M — French startups are experiencing significant job growth and diverse funding, with AI and HealthTech leading key investment areas.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Tech.eu - Tech.eu.